Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/12/2003US20030109500 Compositions and methods for use in targeting vascular destruction
06/12/2003US20030109499 Novel compounds and methods for therapy
06/12/2003US20030109498 Antiviral agent for drug-resistant virus
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109495 Topical treatment for diseases of joints and soft tissues with a proven scientific basis. The carrying agent is DMSO or (dimethyl sulfoxide) in purified form. they are antiinflammatory agents for joints and soft tissues
06/12/2003US20030109494 Composition comprising ascorbic acid with dextran. Pharmaceutical composition for the treatment or prophylaxis of a condition in warm-blooded animals that responds to inhibition of oxygen free radicals, that comprises an amount
06/12/2003US20030109493 Use of polysulphated cyclodextrins for treating osteoarthritis
06/12/2003US20030109492 Methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with beta
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109489 Oligosaccharide derivatives and process for producing the same
06/12/2003US20030109488 Methods for treating dry eye
06/12/2003US20030109487 Deoxy-2'-(fluoromethylene)cytidine; and (b) administering to the patient an effective amount of a platinate; wherein the amounts of (E)-2'-deoxy-2'- (fluoromethylene)cytidine and platinate are selected to provide cellular proliferation
06/12/2003US20030109486 Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
06/12/2003US20030109485 Pharmaceutical combination
06/12/2003US20030109484 Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives
06/12/2003US20030109481 Tumour-cell specific gene expression and its use in cancer therapy
06/12/2003US20030109471 Nucleic acid-based compounds and methods of use thereof
06/12/2003US20030109470 Variants thereof, are described wherein a nucleic acid sequence of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed expression of a nucleic acid
06/12/2003US20030109468 Novel compounds that enhance dimerization of the subunits of HIV-1 reverse transcriptase having mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors
06/12/2003US20030109463 Novel macrolides
06/12/2003US20030109460 A pharmaceutical preparation which ensures stability and solubility of a hexacyclic camptothecin derivative prepared by adding a ring having a water-soluble group to camptothecin, wherein a pH-adjusting substance and, a sugar or sugar alcohol
06/12/2003US20030109448 Enhancing cellular uptake and redistributing gene regulating polyamides from the extranuclear areas in eukaryotic cells to the nucleus thereof. The method consists of administering to the eukaryotic cells a molecular trafficking compound
06/12/2003US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109418 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
06/12/2003US20030109417 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle
06/12/2003US20030109022 Asp2
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030108964 Caspase-inhibitory-factor(cif)and uses thereof
06/12/2003US20030108927 Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
06/12/2003US20030108923 Blocking gene expression
06/12/2003US20030108657 Process for the preparation of one or more statins by frementation
06/12/2003US20030108651 Therapeutic and anti-oxidant for variety of health purposes, including treatment of skin damage; also useful as a natural antibacterial, antiviral and fungicidal agricultural product
06/12/2003US20030108650 Food ingredient enriched in vitamin E and phytosterol; useful as favoured food source meeting recommended daily intake
06/12/2003US20030108629 Compositions and methods for prostate and kidney health and disorders, an herbal preparation
06/12/2003US20030108628 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
06/12/2003US20030108626 Method and composition for dry eye treatment
06/12/2003US20030108624 Treating micro- and macroangiopathic conditions with a bioflavonoid plant extract as antioxidant along with a neovascular controller as an angiogenesis inhibitor; vision defects; wound healing agents; cardiovascular disorders
06/12/2003US20030108623 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
06/12/2003US20030108622 Prophylactic or therapeutic treatment of soft tissue cancer, e.g. breast cancer; improving the effective treatment and reducing the adverse side effects of current anticancer therapy; antiproliferative, -carcinogenic agents
06/12/2003US20030108620 Prophylactic treatment of secondary injury of tissue traumatic event, surgery, transplant, nonproliferative tissue, burns, using of 3-methylsulfonyl-4-piperidinyl benzoyl)guanidine methanesulfonate or N,N-dimethylamiloride
06/12/2003US20030108619 Synergistic mixture of casein polypeptide to promote calcium absorption and genistein which inhibits bone resorption and promotes osteogenesis; prevent decrease in bone density and onset of osteoporosis
06/12/2003US20030108618 Non-pharmacological method for treating depression, skin disorders, and improving overall health and wellness
06/12/2003US20030108615 Also comprising a binder, a taste masking layer, a lubricant, and a binder/dissolution enhancer; storage stability; discoloration inhibition; materials handling; easy dosage adjustment
06/12/2003US20030108611 Bioactive particulates having a cationic surfactant adsorbed on their surfaces to provide superior adhesion to a biological substrate, e.g., an insect, teeth, bone, nails, chitin, feathers, plants, mucous, skin; drug delivery
06/12/2003US20030108610 An aqueous sol for localized drug delivery including a modifier polymer which gels at body temperature; the release rate of the drug is altered and controlled by increasing or decreasing polymer concentration; surgical adhesions
06/12/2003US20030108606 Pharmaceutical formulation
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108602 Controlling releasing
06/12/2003US20030108600 Ubidecarenone compositions and capsules containing the same
06/12/2003US20030108598 Mixture of carotenoid in vegetable oil ; therapy for vision defects
06/12/2003US20030108596 Lipophilic drug compositions
06/12/2003US20030108595 Prevent deposits of amyloid; using sulfonate or sulfate compound
06/12/2003US20030108593 Reduction inhibitory agent for active oxygen eliminating activity
06/12/2003US20030108592 Measurement, dilution, accuracy dosage
06/12/2003US20030108591 Mixture of flavonoids, vegetable protein and sterols
06/12/2003US20030108588 Reduce restenosis coating on medical device
06/12/2003US20030108581 Mammary glands; reducing residues; multisheet pad
06/12/2003US20030108576 Composition
06/12/2003US20030108575 Stabilized oral suspension formulation
06/12/2003US20030108573 Phenol, water solvent extraction using a protease
06/12/2003US20030108572 Antigenic preparations and the isolation of such preparations
06/12/2003US20030108571 Administering extract of Eleutherococcus
06/12/2003US20030108545 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
06/12/2003US20030108543 Mixture of antibody and light sensitivie compound
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108531 Genes for transfection into bony tissues
06/12/2003US20030108512 Prevent metasthasis, degradation of collagen
06/12/2003US20030108510 Synergistic mixture of rutin, escin and bufemin; branching of arteries, veins
06/12/2003US20030108509 Containing sodium dodecyl sulfate
06/12/2003US20030108500 Hair growth stimulant compositions
06/12/2003US20030108496 Compositions comprising phenyl-glycine derivatives
06/12/2003US20030108289 Drop-before-add optical switching and routing system employing grating-based wavelength selective
06/12/2003US20030108275 Optical switch systems using waveguide grating-based wavelength selective switch modules
06/12/2003US20030107798 Wavelength converter using Bragg-grating
06/12/2003CA2672549A1 Amorphous and crystalline forms of losartan potassium and process for their preparation
06/12/2003CA2537913A1 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003CA2471794A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
06/12/2003CA2469395A1 Novel inhibitor compounds specific of secreted non-pancreatic human a2 phospholiphase of group ii
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469349A1 Substituted aryl-cycloalkanes, and use thereof as anticancer agents
06/12/2003CA2469228A1 Azole compound and medicinal use thereof
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469224A1 Trioxane derivatives
06/12/2003CA2469223A1 Trioxane derivatives as antimalaria or anticancer compounds
06/12/2003CA2469193A1 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003CA2469130A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003CA2469119A1 Pharmaceutical compositions comprising active vitamin d compounds
06/12/2003CA2469093A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003CA2469092A1 Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
06/12/2003CA2469085A1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
06/12/2003CA2468996A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003CA2468967A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468907A1 Effectors of innate immunity
06/12/2003CA2468893A1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands
06/12/2003CA2468846A1 Peroxisome proliferator activated receptor agonists
06/12/2003CA2468839A1 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents
1 ... 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 ... 7860